On the other hand, using an AKT inhibitor alone can also increase the levels of phosphorylated proline‐rich Akt substrate of 40 kDa (pPRAS40) through alternative pathways, enhance P53 inactivation, promote cancer progression, and result in resistance to the AKT inhibitor. Here, AKT1 is linked to cancer.